Evidence map›Paper›PMID 38184641›Full record

ArticleNPJ vaccines2024

Absolute quantitation of binding antibodies from clinical samples.

Chan Tang, Annemiek Verwilligen, Jerald Sadoff, Boerries Brandenburg, Eveline Sneekes-Vriese, Tom van den Kerkhof, Lieve Dillen, Lucy Rutten, Jarek Juraszek, Katleen Callewaert and 8 more

Open access · goldAbstract read
In one paragraph

Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Application of Orthoflavivirus Pseudovirus Technology in Antiviral Research.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 3 countries.

Chan Tang *Janssen Vaccines & Prevention, Leiden, The Netherlands.
Annemiek Verwilligen *Janssen Vaccines & Prevention, Leiden, The Netherlands.
Jerald SadoffJanssen Vaccines & Prevention, Leiden, The Netherlands.ORCID http://orcid.org/0000-0002-4839-3013
Boerries BrandenburgJanssen Vaccines & Prevention, Leiden, The Netherlands.
Eveline Sneekes-VrieseJanssen Vaccines & Prevention, Leiden, The Netherlands.ORCID http://orcid.org/0009-0002-0794-6088
Tom van den KerkhofJanssen Vaccines & Prevention, Leiden, The Netherlands.
Lieve DillenJanssen Research & Development, Beerse, Belgium.
Lucy RuttenJanssen Vaccines & Prevention, Leiden, The Netherlands.ORCID http://orcid.org/0000-0002-7363-6822
Jarek JuraszekJanssen Vaccines & Prevention, Leiden, The Netherlands.
Katleen CallewaertJanssen Research & Development, Beerse, Belgium.
Sarah JanssenJanssen Vaccines & Prevention, Leiden, The Netherlands.
Jeroen HuizinghJanssen Vaccines & Prevention, Leiden, The Netherlands.
Zelda EulerJanssen Vaccines & Prevention, Leiden, The Netherlands.
Tom SchilperoordJanssen Vaccines & Prevention, Leiden, The Netherlands.
Marc VerhemeldonckJanssen Research & Development, Beerse, Belgium.
Johannes P M LangedijkJanssen Vaccines & Prevention, Leiden, The Netherlands.ORCID http://orcid.org/0000-0001-8768-0982
Jenny HendriksJanssen Vaccines & Prevention, Leiden, The Netherlands.
Daniel J StiehJanssen Vaccines & Prevention, Leiden, The Netherlands. dstieh@vax.co.ORCID http://orcid.org/0009-0003-8523-1528
Janssen (Netherlands) · NLJanssen (Belgium) · BEHuman Vaccines Project Europe · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The quantitation of antibody responses is a critical requirement for the successful development of vaccines and therapeutics that often relies on the use of standardized reference materials to determine relative quantities within biological samples. The validity of comparing responses across assays using arbitrarily defined reference values is therefore limited. We developed a generalizable method known as MASCALE (Mass Spectrometry Enabled Conversion to Absolute Levels of ELISA Antibodies) for absolute quantitation of antibodies by calibrating ELISA reference sera using mass spectrometry. Levels of proteotypic peptides served as a proxy for human IgG, allowing the conversion of responses from arbitrary values to absolute amounts. Applications include comparison of binding assays at two separate laboratories and evaluation of cross-clade magnitude-breadth responses induced by an investigational HIV-1 vaccine regimen. MASCALE addresses current challenges in the interpretation of immune responses in clinical trials and expands current options available to make suitable comparisons across different settings.

Identifiers

PMID38184641
PMCPMC10771429
OpenAlexW4390638933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.